Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P46100

UPID:
ATRX_HUMAN

ALTERNATIVE NAMES:
ATP-dependent helicase ATRX; X-linked helicase II; X-linked nuclear protein; Znf-HX

ALTERNATIVE UPACC:
P46100; D3DTE2; P51068; Q15886; Q59FB5; Q59H31; Q5H9A2; Q5JWI4; Q7Z2J1; Q9H0Z1; Q9NTS3

BACKGROUND:
ATRX, an ATP-dependent helicase, plays a crucial role in chromatin structure and function, impacting DNA replication and repair. Its involvement in binding DNA quadruplex structures and heterochromatin targeting underscores its importance in maintaining genomic stability. ATRX's function in allele-specific gene expression and its binding to zinc-finger coding genes with atypical chromatin signatures highlight its regulatory complexity in gene expression.

THERAPEUTIC SIGNIFICANCE:
Given its association with diseases such as Alpha-thalassemia myelodysplasia syndrome, ATRX's study is vital for developing novel therapeutic approaches. Its role in chromatin remodeling and gene regulation makes it a promising target for interventions in diseases caused by genetic and epigenetic alterations, paving the way for innovative treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.